PL364662A1 - Synergistyczna kombinacja farmaceutyczna do zapobiegania lub leczenia cukrzycy - Google Patents

Synergistyczna kombinacja farmaceutyczna do zapobiegania lub leczenia cukrzycy

Info

Publication number
PL364662A1
PL364662A1 PL02364662A PL36466202A PL364662A1 PL 364662 A1 PL364662 A1 PL 364662A1 PL 02364662 A PL02364662 A PL 02364662A PL 36466202 A PL36466202 A PL 36466202A PL 364662 A1 PL364662 A1 PL 364662A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
pharmaceutical combination
diabetes
synergistic pharmaceutical
Prior art date
Application number
PL02364662A
Other languages
English (en)
Other versions
PL205826B1 (pl
Inventor
Zoltan Szilvassy
Gyorgy Rabloczky
Nagy Peter Literati
Original Assignee
N-Gene Research Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N-Gene Research Laboratories Inc. filed Critical N-Gene Research Laboratories Inc.
Publication of PL364662A1 publication Critical patent/PL364662A1/pl
Publication of PL205826B1 publication Critical patent/PL205826B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
PL364662A 2001-07-17 2002-07-10 Synergistyczna kombinacja farmaceutyczna do zapobiegania lub leczenia cukrzycy i zastosowanie PL205826B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére

Publications (2)

Publication Number Publication Date
PL364662A1 true PL364662A1 (pl) 2004-12-13
PL205826B1 PL205826B1 (pl) 2010-05-31

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
PL364662A PL205826B1 (pl) 2001-07-17 2002-07-10 Synergistyczna kombinacja farmaceutyczna do zapobiegania lub leczenia cukrzycy i zastosowanie

Country Status (21)

Country Link
US (2) US7635674B2 (pl)
EP (1) EP1408966B1 (pl)
JP (1) JP4598390B2 (pl)
KR (1) KR100920560B1 (pl)
CN (1) CN1270713C (pl)
AT (1) ATE386523T1 (pl)
AU (1) AU2002354884B2 (pl)
BR (1) BR0210744A (pl)
CA (2) CA2682251A1 (pl)
CY (1) CY1107939T1 (pl)
DE (1) DE60225143T2 (pl)
DK (1) DK1408966T3 (pl)
ES (1) ES2300460T3 (pl)
IL (2) IL159412A0 (pl)
MX (1) MXPA04000324A (pl)
NO (1) NO20040153L (pl)
NZ (1) NZ531155A (pl)
PL (1) PL205826B1 (pl)
PT (1) PT1408966E (pl)
RU (1) RU2311907C2 (pl)
WO (1) WO2003007951A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089325A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of PTP1B expression
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
UA96312C2 (ru) * 2006-11-02 2011-10-25 Н-Джин Ресерч Лабораторис Инк. Применение о-(3-пиперидино-2-гидрокси-1-пропил)никотинамидоксима для уменьшения чрезмерной массы тела или ожирения
CN101594868B (zh) * 2006-11-02 2012-12-12 N基因研究实验室公司 具有抗精神病、抗抑郁或抗癫痫活性以及较小副作用的药物组合物
US7753949B2 (en) * 2007-02-23 2010-07-13 The Trustees Of The University Of Pennsylvania Valve prosthesis systems and methods
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
IL321754A (en) 2017-06-30 2025-08-01 Univ California Compositions and methods for modulating hair growth
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
US12649736B2 (en) 2019-12-20 2026-06-09 The Regents Of The University Of California Synthesis of compounds to promote hair growth
MX2022014923A (es) * 2020-05-27 2023-01-04 Corcept Therapeutics Inc Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9.
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
PL205826B1 (pl) 2010-05-31
ATE386523T1 (de) 2008-03-15
KR100920560B1 (ko) 2009-10-08
CA2452558A1 (en) 2003-01-30
US8048873B2 (en) 2011-11-01
JP2004537550A (ja) 2004-12-16
MXPA04000324A (es) 2004-07-23
RU2311907C2 (ru) 2007-12-10
DK1408966T3 (da) 2008-06-16
EP1408966A1 (en) 2004-04-21
US20100048627A1 (en) 2010-02-25
EP1408966B1 (en) 2008-02-20
JP4598390B2 (ja) 2010-12-15
CN1270713C (zh) 2006-08-23
AU2002354884B2 (en) 2007-10-18
CA2682251A1 (en) 2003-01-30
NZ531155A (en) 2005-07-29
KR20040029371A (ko) 2004-04-06
ES2300460T3 (es) 2008-06-16
CA2452558C (en) 2009-12-22
IL159412A (en) 2009-09-22
AU2002354884A2 (en) 2003-03-03
RU2004105149A (ru) 2005-04-20
CY1107939T1 (el) 2013-09-04
DE60225143D1 (de) 2008-04-03
IL159412A0 (en) 2004-06-01
NO20040153L (no) 2004-03-16
US7635674B2 (en) 2009-12-22
PT1408966E (pt) 2008-05-02
DE60225143T2 (de) 2009-02-12
WO2003007951A1 (en) 2003-01-30
US20070015687A1 (en) 2007-01-18
BR0210744A (pt) 2004-07-20
CN1531433A (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
IL159412A0 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
WO1999063826A3 (de) Mittel zur bekämpfung von pflanzenschädlingen
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DZ3312A1 (fr) Compositions pharmaceutiques contenant des derives d&#39;azetidine, les nouveaux derives d&#39;azetidine et leur preparation
CA2367017A1 (en) Inhibitors of impdh enzyme
ZA943812B (en) Fungicidal compositions
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2002062322A3 (en) Glycine betaine and its use as anti-hemorrhagic agent
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2001256727A1 (en) Preventive or therapeutic drugs for cancers containing cyanidin compounds as theactive ingredient
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
IL159841A0 (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета
NO983217L (no) Terapeutiske anti-astmamidler som inneholder selenforbindeler
PL314794A1 (en) Crystalline polymorphous form of (s,s,s)-n-(1-[2-carbocy-3-(n2-mezilolysilamino)propyl]-1-cyclopentylocabonyl)thyrosine
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
WO2003095453A1 (en) Compounds against helicobacter activity